Clinical Report: EQUIPOISE: Real-World Survival Analysis of Prostate Cancer Treatments

Overview

EQUIPOISE is a retrospective cohort study using São Paulo’s statewide Hospital-Based Cancer Registry to compare cancer-specific and overall survival after initial surgery versus radiotherapy plus androgen deprivation therapy (RT + ADT) for intermediate- and high-risk localized prostate cancer. The supplied article describes its contemporary 2014–2023 cohort and propensity-score matching approach, but does not provide comparative survival results; no treatment advantage can therefore be reported from the available material.

Background

Radical prostatectomy and radiotherapy combined with ADT are guideline-endorsed curative approaches for clinically localized intermediate- and high-risk prostate cancer. Randomized comparisons have been difficult to complete, leaving treatment comparisons reliant in part on observational evidence that may be affected by differences in age and comorbidity between treatment groups. Older observational studies may also reflect radiotherapy techniques that predate modern dose-escalated, image-guided treatment. The article identifies a lack of adjusted, population-based comparisons from Latin America as the rationale for its São Paulo registry analysis.

Data Highlights

Key Findings

• The study addresses intermediate- and high-risk localized prostate cancer, for which the article states that both radical prostatectomy and RT + ADT are guideline-endorsed curative treatments.
• The cohort was drawn from a contemporary statewide registry in São Paulo and included diagnoses from 2014 through 2023.
• Treatment assignment followed the initial modality: men initially receiving prostatectomy remained in the surgery group regardless of subsequent treatment, while the RT + ADT group received radiotherapy plus ADT without surgery.
• The intention-to-treat grouping was designed to retain post-prostatectomy treatment within the surgery-based strategy; the article notes that first-course treatment recording incompletely captures later salvage therapy, making reported proportions lower bounds.
• Propensity-score matching was planned separately by risk stratum, using clinical and demographic variables, care category, and facility accreditation.
• The supplied excerpt contains methods but no survival estimates or comparative outcome results; it does not establish whether either treatment strategy was associated with better survival.

Clinical Implications

The supplied material supports describing the study design and its intended comparison, but not using it to counsel that one treatment provides superior survival. The article’s stated context is that treatment decisions remain informed by observational evidence while randomized comparative findings are limited; the excerpt does not provide EQUIPOISE outcome data for clinical application.

Conclusion

EQUIPOISE was designed to compare survival after initial surgery versus RT + ADT in a contemporary, population-based Brazilian cohort using propensity-score matching and intention-to-treat grouping. Because the provided text omits the comparative results, its survival findings cannot be summarized here.

Related Resources & Content

1. ASCO Publications, 2016 — Quality-adjusted survival comparison between androgen deprivation with radiation therapy versus radiation therapy alone for locally advanced prostate cancer: Decision analysis from RTOG 85-31 trial
2. ASCO Publications, 2018 — Survival after surgical or radiotherapeutic treatment for high-risk localized prostate cancer: A National Cancer Database analysis with comprehensive treatment group imbalances adjustments
3. European Association of Urology, 2026 — EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer
4. Hamdy et al., New England Journal of Medicine, 2023 — Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer
5. Systematic review, PubMed, 2024 — A Systematic Review of Clinical Trials Comparing Radiation Therapy Versus Radical Prostatectomy in Prostate Cancer
6. ASCO Publications — Survival after surgical or radiotherapeutic treatment for high-risk localized prostate cancer: A National Cancer Database analysis with comprehensive treatment group imbalances adjustments.
7. ASCO Publications — Radiotherapy versus radical prostatectomy for Gleason score 9-10 prostate adenocarcinoma: A multi-institutional comparative analysis of 1001 patients treated in the modern era.
8. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer
9. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer
10. A Systematic Review of Clinical Trials Comparing Radiation Therapy Versus Radical Prostatectomy in Prostate Cancer